ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TOVX Theriva Biologics Inc

0.41
-0.038 (-8.48%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 66,521
Bid Price
Ask Price
News -
Day High 0.44

Low
0.1972

52 Week Range

High
1.20

Day Low 0.4111
Company Name Stock Ticker Symbol Market Type
Theriva Biologics Inc TOVX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.038 -8.48% 0.41 18:19:02
Open Price Low Price High Price Close Price Prev Close
0.4351 0.4111 0.44 0.4152 0.448
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
342 66,521 $ 0.4234414 $ 28,168 - 0.1972 - 1.20
Last Trade Time Type Quantity Stock Price Currency
19:20:00 34 $ 0.4199 USD

Theriva Biologics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
17.38M 17.04M - 0 -18.35M -1.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Theriva Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TOVX Message Board. Create One! See More Posts on TOVX Message Board See More Message Board Posts

Historical TOVX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.450.460.41110.441395727,208-0.04-8.89%
1 Month0.48010.54460.41110.466100653,437-0.0701-14.60%
3 Months0.4150.68450.410.534216799,927-0.005-1.20%
6 Months0.4850.68450.19720.508130977,640-0.075-15.46%
1 Year0.711.200.19720.826347231,252-0.30-42.25%
3 Years0.801.260.19720.816938176,604-0.39-48.75%
5 Years0.801.260.19720.816938176,604-0.39-48.75%

Theriva Biologics Description

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Your Recent History

Delayed Upgrade Clock